BACKGROUND: Several experiments were designed to determine whether the systemic, postischemic administration of PJ34,which is a poly-adenosine diphosphate (ADP)-ribose polymerase inhibitor, decreased tissue injury and inflammation after hind-limb ischemia reperfusion (I/R). METHODS: C57BL6 mouse limbs were subjected to 1.5 h ischemia followed by 24-h reperfusion. The treatment group (PJ) received intraperitoneal PJ34 (30 mg/kg) immediately before reperfusion, as well as 15 min and 2 h into reperfusion. The control group (CG) received lactated Ringer's alone at the same time intervals as PJ34 administration. The skeletal muscle levels of adenosine triphosphate (ATP), macrophage inflammatory protein-2 (MIP-2), keratinocyte derived chemokine (KC), and myeloperoxidase (MPO) were measured. Quantitative measurement of skeletal muscle tissue injury was assessed by microscopic analysis of fiber injury. RESULTS: ATP levels were higher in limbs of PJ versus CG mice (absolute ATP: 4.7 +/- 0.35 vs 2.3 +/- 0.15-ng/mg tissue, P = .002). The levels of MIP-2, KC, and MPO were lower in PJ versus CG mice (MIP-2: 1.4 +/- 0.34 vs 3.67 +/- 0.67-pg/mg protein, P = .014; KC: 4.97 +/- 0.97 vs 12.65 +/- 3.05-pg/mg protein, P = .037; MPO: 46.27 +/- 10.53 vs 107.34 +/- 13.58-ng/mg protein, P = .008). Muscle fiber injury was markedly reduced in PJ versus CG mice (4.25 +/- 1.9% vs 22.68 +/- 3.0% total fibers, P = .0004). CONCLUSION: Systemic postischemic administration of PJ34 preserved skeletal muscle energy levels, decreased inflammatory markers, and preserved tissue viability post-I/R. These results support PARP inhibition as a viable treatment for skeletal muscle I/R in a clinically relevant post hoc scenario. Copyright 2010 Mosby, Inc. All rights reserved.
BACKGROUND: Several experiments were designed to determine whether the systemic, postischemic administration of PJ34,which is a poly-adenosine diphosphate(ADP)-ribose polymerase inhibitor, decreased tissue injury and inflammation after hind-limb ischemia reperfusion (I/R). METHODS: C57BL6 mouse limbs were subjected to 1.5 h ischemia followed by 24-h reperfusion. The treatment group (PJ) received intraperitoneal PJ34 (30 mg/kg) immediately before reperfusion, as well as 15 min and 2 h into reperfusion. The control group (CG) received lactated Ringer's alone at the same time intervals as PJ34 administration. The skeletal muscle levels of adenosine triphosphate (ATP), macrophage inflammatory protein-2 (MIP-2), keratinocyte derived chemokine (KC), and myeloperoxidase (MPO) were measured. Quantitative measurement of skeletal muscle tissue injury was assessed by microscopic analysis of fiber injury. RESULTS:ATP levels were higher in limbs of PJ versus CG mice (absolute ATP: 4.7 +/- 0.35 vs 2.3 +/- 0.15-ng/mg tissue, P = .002). The levels of MIP-2, KC, and MPO were lower in PJ versus CG mice (MIP-2: 1.4 +/- 0.34 vs 3.67 +/- 0.67-pg/mg protein, P = .014; KC: 4.97 +/- 0.97 vs 12.65 +/- 3.05-pg/mg protein, P = .037; MPO: 46.27 +/- 10.53 vs 107.34 +/- 13.58-ng/mg protein, P = .008). Muscle fiber injury was markedly reduced in PJ versus CG mice (4.25 +/- 1.9% vs 22.68 +/- 3.0% total fibers, P = .0004). CONCLUSION: Systemic postischemic administration of PJ34 preserved skeletal muscle energy levels, decreased inflammatory markers, and preserved tissue viability post-I/R. These results support PARP inhibition as a viable treatment for skeletal muscle I/R in a clinically relevant post hoc scenario. Copyright 2010 Mosby, Inc. All rights reserved.
Authors: Prakash Jagtap; Francisco Garcia Soriano; László Virág; Lucas Liaudet; Jon Mabley; Eva Szabó; György Haskó; Anita Marton; Clara Batista Lorigados; Ferenc Gallyas; Balázs Sümegi; Dale G Hoyt; Erkan Baloglu; John VanDuzer; Andrew L Salzman; Garry J Southan; Csaba Szabó Journal: Crit Care Med Date: 2002-05 Impact factor: 7.598
Authors: Roy D Goldfarb; Anita Marton; Eva Szabó; László Virág; Andrew L Salzman; Dana Glock; Imran Akhter; Robert McCarthy; Joseph E Parrillo; Csaba Szabó Journal: Crit Care Med Date: 2002-05 Impact factor: 7.598
Authors: Gábor Szabó; Susanne Bährle; Nicole Stumpf; Karin Sonnenberg; Eva Szabó E; Pál Pacher; Tamás Csont; Richard Schulz; Thomas J Dengler; Lucas Liaudet; Prakash G Jagtap; Garry J Southan; Christian F Vahl; Siegfried Hagl; Csaba Szabó Journal: Circ Res Date: 2002-01-11 Impact factor: 17.367
Authors: J G Mabley; P Jagtap; M Perretti; S J Getting; A L Salzman; L Virág; E Szabó; F G Soriano; L Liaudet; G E Abdelkarim; G Haskó; A Marton; G J Southan; C Szabó Journal: Inflamm Res Date: 2001-11 Impact factor: 4.575
Authors: Magdi M I Yassin; Denis W Harkin; Aires A B Barros D'Sa; M Isla Halliday; Brian J Rowlands Journal: World J Surg Date: 2001-10-25 Impact factor: 3.352
Authors: Hassan Albadawi; Rahmi Oklu; Nicholas R Cormier; Ryan M O'Keefe; James T Heaton; James B Kobler; William G Austen; Michael T Watkins Journal: J Surg Res Date: 2014-01-17 Impact factor: 2.192